Last Events:
2023-08-09 Trend Power changed from slow to medium strength.
2023-08-05 Trend pattern changed from канал to нисходящий треугольник.
2023-08-05 Signal in Stochastic changed from bullish to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: main and signal line crossing.
2023-08-03 Trend pattern changed from расходящийся клин с наклоном вверх to канал.
2023-08-03 Signal in Stochastic changed from bullish reversal to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: up-crossing the middle level.
2023-08-03 Signal in MACD changed from bearish weakening to bearish recovery. Oscillator MACD is in the negative territory it's lower than the signal line and falls. These factors mean that negative mood prevails. Last signal: main and signal line crossing.
2023-08-03 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.
2023-08-03 Trend Power changed from medium strength to slow.
Current temperature: 1.17
ST: 0, Cor:
Analyst Recommendations:
|
|
| Number of estimates |
6 |
| Target Price Mean |
7.67 |
| Mean unverified/preliminary |
7.63 / 7.67 |
| Target Price Low / High |
2.00 / 25.00 |
| Median / STD DEV |
4.00 / 8.73 |
Tech Forecasts:
More signals
| |
< 1M |
1-3M |
> 3M |
| total |
Sell |
Sell |
Buy |
| rsi |
Sell |
ActivelyBuy |
ActivelyBuy |
| macd |
None |
None |
None |
| stoch |
None |
None |
None |
| ma20 |
Buy |
Sell |
Sell |
| ma50 |
Sell |
None |
None |
| ma100 |
Sell |
Sell |
None |
| Candlestick Pattern | Dec. 16, 2024 Three Stars - |
|---|
| |
|---|
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.